Skip to content
AnalystLens

CENTENE CORP 8-K Report, Regulation FD Disclosure (Mar 11, 2024)

Reports
Regulation FD
Filing Date
Filed March 11, 2024
Period End
March 11, 2024
Security
CNC
In the record · 2016–202610-K1110-Q328-K217

CNC filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 217 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Jul ’18Jul ’18
  2. Material agreement8-K · Oct ’20Oct ’20
  3. Leadership change8-K · Nov ’22Nov ’22
  4. Leadership change8-K · Aug ’26Aug ’26

01—Abstract

Summary

Summary of the 8-K filed March 11, 2024. Cited figures are marked; the original filing is the authoritative source.

Centene Corporation (CNC) issued an 8-K filing on March 11, 2024, to announce participation in the Barclays 26th Annual Global Healthcare Conference on March 12, 2024.

The primary purpose of this disclosure is to reaffirm the company's previously issued 2024 adjusted diluted earnings per share (EPS) guidance, which is expected to be greater than $6.70a. This reaffirmation provides investors with continued confidence in the company's near-term earnings outlook. The filing also details Centene's rationale for presenting non-GAAP financial measures, emphasizing their utility in assessing ongoing operations and performance consistency, while cautioning investors to consider these alongside GAAP figures and acknowledging the difficulty in reconciling forward-looking non-GAAP guidance to GAAP measures.

02—Key points

Key Highlights

  1. Centene Corp. reaffirms its 2024 adjusted diluted EPS guidance of greater than $6.70.
  2. The reaffirmation is made in conjunction with the company's presentation at the Barclays 26th Annual Global Healthcare Conference on March 12, 2024.
  3. The company will provide a live audio webcast of the presentation, with a replay available on its investor relations website.
  4. Centene explains its use of non-GAAP financial measures, such as adjusted diluted EPS, to provide a clearer view of ongoing operational performance.
  5. The company acknowledges that its non-GAAP measures may differ from those of other companies.
  6. Centene states that reconciliation of 2024 adjusted diluted EPS guidance to the most directly comparable GAAP measure is not feasible without unreasonable effort.
  7. The filing includes standard forward-looking statement disclaimers, highlighting various risks and uncertainties that could impact future performance.

03—Questions

Frequently Asked Questions

  1. What is the main takeaway from this 8-K filing?

    The main takeaway is that Centene Corporation is reaffirming its previously issued 2024 adjusted diluted EPS guidance of greater than $6.70, indicating continued confidence in its financial outlook for the year.

  2. Why is Centene using non-GAAP financial measures in this disclosure?

    Centene uses non-GAAP financial measures to provide investors with a better understanding of the ongoing nature of its operations and to measure performance more consistently across different periods. They believe these measures help focus on the core business operations.

  3. Can investors expect an update on the 2024 guidance if it changes?

    The guidance provided is only effective as of March 12, 2024. Centene states that it will not be updated or affirmed unless and until the company publicly announces updated or affirmed guidance. Investors should monitor future communications.

  4. What are some of the risks mentioned in the filing that could affect Centene's performance?

    The filing lists numerous risks, including changes in government healthcare programs, regulatory changes, increased healthcare costs, competition, operational challenges, data security incidents, and potential legal or regulatory investigations, among others. These factors could impact the company's ability to achieve its financial goals.

04—Continue

← View all 8-K filings